- 1 Multimorbidity and blood pressure control: a cross-sectional analysis among 67,385 adults with
- 2 hypertension in Canada
- 3 Short title: Multimorbidity and blood pressure control in primary care
- 4 Tu N Nguyen ^{1,2}, Sumeet Kalia ², Peter Hanlon ³, Bhautesh D Jani ³, Barbara I Nicholl ³, Chelsea D.
- 5 Christie ², Babak Aliarzadeh ², Rahim Moineddin ², Christopher Harrison ⁴, Clara Chow ¹, Martin
- 6 Fortin⁵, Frances S Mair³, Michelle Greiver^{2,6}
- 8 Westmead Applied Research Centre, Sydney Medical School, Faculty of Medicine and Health,
- 9 University of Sydney, Sydney, New South Wales, Australia.
- 10 ² Department of Family and Community Medicine, Temerty Faculty of Medicine, University of
- 11 Toronto, Toronto, ON, Canada
- ³ General Practice and Primary Care, School of Health and Wellbeing, University of Glasgow, UK
- ⁴ Menzies Centre for Health Policy and Economics, School of Public Health, Faculty of Medicine and
- 14 Health, University of Sydney, Sydney, New South Wales, Australia
- ⁵ Department of family medicine and emergency medicine, Université de Sherbrooke, Saguenay, QC,
- 16 Canada

- 17 ⁶ Department of Family and Community Medicine, North York General Hospital, Toronto, ON,
- 18 Canada

19

20

21

22

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

Abstract Background. There has been conflicting evidence on the association between multimorbidity and blood pressure (BP) control. This study aimed to investigate this associations in people with hypertension attending primary care in Canada, and to assess whether individual long-term conditions are associated with BP control. Methods. A cross-sectional study in people with hypertension attending primary care in Toronto between January 01 2017 and December 31 2019. Uncontrolled BP was defined as systolic BP≥140 mmHg or diastolic BP≥90 mmHg. A list of 11 a priori selected chronic conditions was used to define multimorbidity. Multimorbidity was defined as having ≥1 long-term condition in addition to hypertension. Logistic regression models were used to estimate the association between multimorbidity (or individual long-term conditions) with uncontrolled BP. **Results.** A total of 67,385 patients with hypertension were included. They had a mean age of 70, 53.1% were female, 80.6% had multimorbidity, and 35.7% had uncontrolled BP. Patients with multimorbidity had lower odds of uncontrolled BP than those without multimorbidity (adjusted OR 0.72, 95% CI 0.68-0.76). Among the long-term conditions, diabetes (aOR 0.73, 95%CI 0.70-0.77), heart failure (aOR 0.81, 95%CI 0.73-0.91), ischemic heart disease (aOR 0.74, 95%CI 0.69-0.79), schizophrenia (aOR 0.79, 95%CI 0.65-0.97), depression/anxiety (aOR 0.91, 95%CI 0.86-0.95), dementia (aOR 0.87, 95%CI 0.80-0.95), and osteoarthritis (aOR 0.89, 95%CI 0.85-0.93) were associated with a lower likelihood of uncontrolled BP. Conclusion. We found that multimorbidity was associated with better BP control. Several conditions were associated with better control, including diabetes, heart failure, ischemic heart disease, schizophrenia, depression/anxiety, dementia, and osteoarthritis. Keywords: hypertension, high blood pressure, blood pressure control, multimorbidity, primary care

Introduction

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Hypertension is a risk factor for cardiovascular disease and other chronic health conditions. The prevalence of hypertension increases with age, with a prevalence of only 27% in people younger than 60 years, but 74% in people aged 80 and older. Globally, blood pressure (BP) control is still suboptimal, with control rates of only approximately 20% for people with hypertension.² Poor control of hypertension can increase the risk of heart failure, coronary heart disease, peripheral artery disease, renal failure, stroke and dementia, and therefore, increase the risk of developing multimorbidity in people with hypertension.³ Multimorbidity, defined as having two or more chronic conditions, has become a primary healthcare concern.^{4,5} Two out of three people with hypertension have additional long-term condition.⁶ A systematic review of 45 studies conducted from 2007 to 2017 showed that the overall prevalence of multimorbidity was 66.1% (when multimorbidity was defined as having ≥ 2 chronic conditions), and 44.2% (when multimorbidity was defined as having ≥ 3 chronic conditions) in older adults in highincome countries. In the United States, 81 million adults were estimated to have multimorbidity in 2020.8 In Canada, the prevalence of multimorbidity is also high, with a reported prevalence ranging from around 30% to 70% in primary care settings, and around 17% to 59% in the general population.⁹ Multimorbidity increases healthcare costs and healthcare utilisation including hospitalisations. 10,11 Several studies have examined the impact of multimorbidity on BP control, and there has been conflicting evidence on the association between multimorbidity and hypertension control. 12-17 While some studies show that the presence of multimorbidity was positively associated with BP control, 12,16,18 other studies suggested that people with more comorbidities had poorer management and control of hypertension. 15,17 There is minimal evidence of this association in the Canadian population. Therefore, in this study, we aimed to investigate the association between multimorbidity and BP control in patients attending primary care in Canada, and to assess if individual comorbidities are associated with BP control.

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

Materials and Methods Data source This study used data from the University of Toronto Practice-Based Research Network (UTOPIAN), a primary care electronic medical records (EMRs) database. The UTOPIAN database contains deidentified records from participating family medicine clinics in Ontario, Canada, with most providers practicing in the Greater Toronto Area. 19 Data include de-identified patient-level information on various factors including demographics, medical diagnoses, procedures, medications, immunizations, laboratory test results, vital signs, risk factors, and clinical notes. Study design and eligible patients This is a cross-sectional study using the UTOPIAN 2021Q4 database with a start date of January 01 2017 and an end date of December 31 2019. This end date was chosen to avoid the COVID-19 pandemic-related effects on the data. The data were accessed for research purposes from June 17 2022 to December 16 2022. We identified a cohort of patients who met the following selection criteria; had hypertension before December 31 2019; had blood pressure recorded between Jan 01 2017 and Dec 31 2019; and were at least 45 years old when their blood pressure was measured. Figure 1 provides a flowchart for the cross-sectional cohort. We defined the hypertension phenotype using the following criteria (Appendix 2): 1. Free text documentation of hypertension was found within the (past or present) health condition section of the cumulative patient profile, including the following terms: hypertension, hypertensive, htn; OR 2. Anti-hypertensive medication was prescribed and an elevated blood pressure reading was recorded at any point in the EMR (elevated blood pressure reading is defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg); OR

hypertension (ICD-9 code 401) was recorded at any point in the EMR; OR

3. Anti-hypertensive medication was prescribed and a billing record with the diagnosis code for

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

4. A billing record with the diagnosis code for hypertension (ICD-9 code 401) and an elevated blood pressure reading was recorded at any point in the EMR (elevated blood pressure reading is defined as systolic blood pressure \geq 140 mmHg or diastolic blood pressure \geq 90 mmHg) **Multimorbidity** Multimorbidity was defined as having one or more long-term conditions in addition to hypertension. This definition of multimorbidity is similar to definitions used in other studies (REFs).²⁰⁻²² A list of 11 a priori selected chronic conditions was used to define multimorbidity, in alignment with the Centers for Disease Control and Prevention (CDC) recommendations for defining and measuring multiple chronic conditions when using Medicare claims. 23 These long-term condition are: ischemic heart disease, heart failure, atrial fibrillation, diabetes, chronic obstructive pulmonary disease, asthma, chronic kidney disease (chronic kidney disease stage 3 or more, or dependence on transplant or dialysis), cancers (including breast cancer, cervical cancer, lung cancer, colorectal cancer, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer), osteoarthritis, dementia, depression and/or anxiety, and schizophrenia. Covariate definitions We used the most recent information on Body Mass Index (BMI) and smoking status as of December 31, 2019. BMI was grouped into underweight (\leq 18.4), normal (18.5-24.9), overweight (25.0-29.9), obese class I (30.0-34.9), obese class II (35.0-39.9), and obese class III (≥40.0). We calculated age (in years) on the date when the blood pressure measurement was recorded between January 01, 2017 and December 31, 2019. We used rurality and neighbourhood income quintiles (as an indicator of socioeconomic status) using data from the 2016 Statistics Canada Census.²⁴ We identified different classes of hypertension medication (including angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor blocker (ARBi), calcium channels, beta-blockers, diuretics, and other classes of hypertension medication) that were prescribed during the six months prior to the blood pressure measurement. The full description of drug names for each class of hypertension

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

medication is provided in Appendix section (i), along with the algorithm used to determine the presence of hypertension in EMRs (see Appendix section (ii)). Outcome measure The primary outcome measurement was the most recent BP measure recorded during the study period (January 01, 2017 to December 31, 2019). Uncontrolled BP was defined as having either systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg for the last BP measurement prior to December 31 2019. The BP treatment target was chosen to align with the Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension that reflected the practice during the study period. ²⁵ The SBP treatment goal is a pressure level of < 140 mm Hg (Grade C). The DBP treatment goal is a pressure level of < 90 mm Hg (Grade A). These targets were established using Office-based BP Measurements (OBPM).²⁵ For patients with multiple BP readings recorded on the same day at the same visit (e.g. using an automated BPtru machine), we took the average measurement of the systolic and diastolic blood pressure measures on that day. We also conducted a sensitivity analysis, with a BP target of < 130/80 mmHg, as recommended by the 2018 ESC/ESH Guidelines for the management of arterial hypertension²⁶, and the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.²⁷ Statistical analysis We used descriptive statistics to summarize patient demographics and clinical characteristics associated with controlled and uncontrolled blood pressure. We used means, standard deviations, and median, minimum and maximum to summarize continuous variables, while frequencies and percentages were used to summarize categorical variables. To reduce the risk of re-identification, our reports exclude any cell count of five or fewer. Comparisons between patients with controlled and uncontrolled BP were assessed using Pearson chi-square tests for categorical covariates and using two-sample t-tests for continuous covariates.

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

We fitted logistic regression models using the Generalized Estimating Equations (GEE) with an exchangeable working correlation matrix to assess the association between multimorbidity (or individual long-term condition) on uncontrolled BP. We reported both the unadjusted odds ratios and adjusted odds ratios. To account for multicollinearity, we fitted separate logistic models using GEE for multimorbidity and different comorbidities, respectively. We a priori specified age, sex, income quintiles, smoking BMI as potential confounders (i.e. common cause) for multimorbidity and for the outcome of BP control, while different classes of hypertension medications were considered potential mediators on the pathway between multimorbidity and BP control (see Supplementary Figure S1). In GEE models, we adjusted for the following covariates: age, sex, income quintiles, smoking status, BMI, number of primary care visits, along with the multimorbidity status. In a sensitivity analysis, we used a reduced threshold for blood pressure control (<130/80 mm Hg) and excluded BMI and smoking status in the regression models to include patients that did not have BMI or smoking status recorded. Ethics approval This study was approved by the Research Ethics Board at the University of Toronto (protocol number 00043354). Results Sample characteristics A total of 67,385 patients who satisfied the selection criteria were included in this study. Patients in the sample had a mean age of 70.1 years (SD 11.8) and 53.1% were female. The prevalence of overweight and obesity was 66%, with a greater proportion of patients with class II and class III obesity in the uncontrolled BP group compared to the controlled BP group. There was no difference in socioeconomic status between the two groups. (Table 1) Multimorbidity

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

The overall prevalence of multimorbidity was 80.6%. Patients with multimorbidity had a higher number of annual primary care visits than patients without multimorbidity in 2017, 2018 and 2019 (Supplementary Table S2). As an example, 8.0% of the patients with multimorbidity had more than 9 visits in 2019 compared to 1.9% of patients without multimorbidity Uncontrolled blood pressure Overall, 35.7% of patients had uncontrolled BP (34.1% in patients with multimorbidity and 42.7% in patients without multimorbidity, p<0.001). Figure 2 presents the percentages of uncontrolled BP in patients with and without multimorbidity. Across the three age groups, patients with multimorbidity had lower rates of uncontrolled BP compared to patients without multimorbidity. The association between multimorbidity and hypertension control Patients with multimorbidity had lower odds of uncontrolled BP compared to those without multimorbidity (adjusted OR = 0.72, 95% CI 0.68 to 0.76, adjusted for age, sex, income quintiles, smoking status, body mass index, and number of visits). Younger patients had lower odds of having uncontrolled BP than older patients. Obese patients (in class I, II and III) had higher odds of uncontrolled BP than those with normal BMI. Current smokers had higher odds of having uncontrolled BP compared to non-smokers. Increasing number of visits to primary care doctors was associated with lower odds of uncontrolled BP. (Figure 3) The association between types of long-term conditions and hypertension control Among the long-term conditions, seven conditions were significantly associated with lower likelihood of uncontrolled BP: diabetes (adjusted OR 0.73, 95%CI 0.70-0.77), heart failure (adjusted OR 0.81, 95%CI 0.73-0.91), ischemic heart disease (adjusted OR 0.74, 95%CI 0.69-0.79), schizophrenia (adjusted OR 0.79, 95%CI 0.65-0.97), depression/anxiety (adjusted OR 0.91, 95%CI 0.86-0.95), dementia (adjusted OR 0.87, 95%CI 0.80-0.95), and osteoarthritis (adjusted OR 0.89, 95%CI 0.85-

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

0.93). The remaining long-term conditions (atrial fibrillation, COPD, asthma, chronic kidney disease, and cancer) were not associated with uncontrolled BP. (Figure 4) Sensitivity analysis Sensitivity analyses showed consistent results (Supplementary Tables S3, S4). In GEE models using ≥ 130/80 mmHg as the threshold for sub-optimal blood pressure control, multimorbidity was still significantly associated with reduced likelihoods of uncontrolled BP (adjusted ORs 0.56, 95%CI 0.54-0.59), adjusting for age, sex, income quintiles, body mass index, and number of visits). Discussion Summary of findings In this study, we aimed to investigate the association between multimorbidity and uncontrolled BP, and to assess if individual long-term conditions are associated with uncontrolled BP. Our analysis in 67,385 Canadians aged 45 years or more with hypertension attending primary care from 2017 to 2019 showed an association between the presence of comorbidities and better blood pressure control. Multimorbidity was associated with approximately 30% lower odds of uncontrolled BP. The individual long-term conditions that were significantly associated with lower likelihood of uncontrolled BP include diabetes, heart failure, ischemic heart disease, schizophrenia, depression/anxiety, dementia, or osteoarthritis. Comparison to the literature Our finding aligns with other studies that examined this association, which reported that multimorbidity was one of the strongest predictors of controlled BP in patients with hypertension. Tapela and colleagues found that multimorbidity was positively associated with BP control among participants with hypertension in the UK Biobank, and the types of comorbidities that were significantly associated with controlled BP included cardiovascular disease (OR 2.11, 95% CI 2.04 to 2.19), diabetes (OR 1.32, 95% CI 1.27 to 1.36), migraines (OR 1.68, 95% CI 1.56 to 1.81), and depression (OR 1.27, 95% CI 1.20 to 1.34).²⁸ Another study conducted by Sarkar and colleagues in 31,676 patients with hypertension in the Lambeth Data-Net, a patient-level primary care database in the UK, found that 16,140 (51 %) had multimorbidity, and hypertensive patients with multimorbidity had lower BP than those with hypertension alone. 12. Mini and colleagues also reported that blood pressure control was better in participants who reported any comorbidity (OR 2.37, 95%CI 1.51–3.71) compared to those who did not report any. 16 However, several other studies reported the opposite findings - people with more comorbidities had poorer management and control of hypertension. In a study of 223,286 patients with hypertension in Hongkong, Wong et al. found that the proportion of patients having poor BP control increased from 35.0% to 65.0% and 69.1% when the number of medical conditions increased from zero to one and two, respectively. 15 However, this study enrolled adult patients prescribed their first antihypertensive agents; hence people with comorbidities (such as diabetes, heart failure, coronary heart disease) who were already on a relevant medication (betablockers, ACE inhibitors) for these reasons would be excluded from the hypertension cohort. A crosssectional analysis of the World Health Organisation Study of Global Ageing and Adult Health (WHO SAGE) Wave 1 (2007–10) in 41,557 adults (9778 with hypertension) from 6 middle-income countries (including China, Ghana, India, Mexico, Russia and South Africa) reported that more comorbidities were associated with increased odds of uncontrolled hypertension.¹⁷ The BP control rate in our study is also consistent with the literature. In a recent report from the NCD Risk Factor Collaboration using data from 1990 to 2019 on people aged 30-79 years from populationrepresentative studies with measurement of blood pressure, the estimated rate of uncontrolled BP in Canada was 25%-30% in 2019.29 A report from the Danish General Practice Database of 37,651 patients with hypertension from 231 general practices showed that the overall BP control rate was 33.2%. 18 A cross-sectional population-based study including 99,468 participants with hypertension enrolled in the UK Biobank reported that the overall control rate of BP was 38.1%.²⁸

Implication for practice and research

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

The results from this study may reflect the achievement of primary care in controlling cardiovascular risk factors in patients with multimorbidity, including regular BP measures and treatment. Comorbidities may be associated with more frequent healthcare utilisation and hence increase the monitoring of chronic conditions, including BP measurement and counselling on lifestyle modifications and medication adherence. Another explanation could be the study's participation selection processes. Among people with hypertension as their only chronic health condition, those with poorer BP control may be more motivated to attend primary care and hence were included in this cohort. Thus, the observed associations could be explained by selection bias - hypertensive patients with no comorbidities, but uncontrolled BP may have been more likely to seek primary care compared to hypertensive patients with no comorbidities and controlled BP. These lead to opportunities to measure BP and obtain scripts, reminders given to them on taking medications, and better lifestyle modifications. More studies are needed to explore the mechanisms underlying the associations between multimorbidity and BP control. Strengths and limitations This is one of the largest analyses of hypertension control in adults attending primary care in Canada, with comprehensive sociodemographic and high-quality detailed clinical information, including comorbidities. However, the data was only collected from patients in Ontario and is not nationally representative. Another limitation of this study is that EMR data may be incomplete, and we might be unable to capture all cases of hypertension and/or prescriptions of anti-hypertensive medications. Lifestyle modification, which is an essential strategy in the management of hypertension and can influence BP control, could not be captured through the EMR data. Duration and severity of hypertension and other chronic diseases were also not captured. Therefore, results should be replicated and cautiously interpreted before generalizing to all patients in primary care. Conclusion In this large-scale study of patients attending primary care with hypertension, multimorbidity was associated with better BP control. Several long-term conditions were associated with better control, including diabetes, heart failure, ischemic heart disease, schizophrenia, depression/anxiety, dementia, and osteoarthritis. Further large-scale mixed methods studies are needed to explore the mechanisms

- 279 underlying the associations between multimorbidity and BP control, and to understand barriers to BP
- 280 control in primary care.
- 282 Acknowledgements. Dr Tu Nguyen is supported by the University of Sydney Global Development
- 283 Awards.

284 References

- 285 1. Oliveros E, Patel H, Kyung S, et al. Hypertension in older adults: Assessment, management,
- and challenges. Clinical Cardiology 2019; 43: 99-107.
- 287 2. Nguyen TN, Chow CK. Global and national high blood pressure burden and control. *The*
- 288 *Lancet* 2021; **398**(10304): 932-3.
- 3. Sierra C. Hypertension and the Risk of Dementia. Front Cardiovasc Med 2020; 7: 5-.
- 290 4. Fortin M, Dubois MF, Hudon C, Soubhi H, Almirall J. Multimorbidity and quality of life: a
- closer look. Health and quality of life outcomes 2007; 5: 52.
- 5. Skou ST, Mair FS, Fortin M, et al. Multimorbidity. *Nat Rev Dis Primers* 2022; **8**(1): 48.
- 293 6. Kennard L, O'Shaughnessy KM. Treating hypertension in patients with medical
- 294 comorbidities. *BMJ* 2016; **352**: i101.
- 295 7. Ofori-Asenso R, Chin KL, Curtis AJ, Zomer E, Zoungas S, Liew D. Recent Patterns of
- 296 Multimorbidity Among Older Adults in High-Income Countries. *Popul Health Manag* 2018.
- 297 8. Vogeli C, Shields AE, Lee TA, et al. Multiple chronic conditions: prevalence, health
- 298 consequences, and implications for quality, care management, and costs. Journal of general internal
- 299 *medicine* 2007; **22** Suppl **3**: 391-5.
- 300 9. Mokraoui NM, Haggerty J, Almirall J, Fortin M. Prevalence of self-reported multimorbidity
- in the general population and in primary care practices: a cross-sectional study. BMC Res Notes 2016;
- **9**: 314.
- 303 10. Marina S-B, Mark A, Alessandra B, et al. Impact of multimorbidity on healthcare costs and
- 304 utilisation: a systematic review of the UK literature. British Journal of General Practice 2021;
- **71**(702): e39.

- 306 11. Rodrigues LP, de Oliveira Rezende AT, Delpino FM, et al. Association between
- 307 multimorbidity and hospitalization in older adults: systematic review and meta-analysis. Age and
- 308 Ageing 2022; **51**(7): afac155.
- 309 12. Sarkar C, Dodhia H, Crompton J, et al. Hypertension: a cross-sectional study of the role of
- multimorbidity in blood pressure control. *BMC family practice* 2015; **16**: 98-.
- 311 13. Paulsen MS, Andersen M, Thomsen JL, et al. Multimorbidity and Blood Pressure Control in
- 312 37 651 Hypertensive Patients From Danish General Practice. Journal of the American Heart
- 313 *Association*; **2**(1): e004531.
- 314 14. Tran J, Norton R, Canoy D, et al. Multi-morbidity and blood pressure trajectories in
- 315 hypertensive patients: A multiple landmark cohort study. *PLoS medicine* 2021; **18**(6): e1003674-e.
- 316 15. Wong MC, Wang HH, Cheung CS, et al. Factors associated with multimorbidity and its link
- with poor blood pressure control among 223,286 hypertensive patients. *Int J Cardiol* 2014; **177**(1):
- 318 202-8.
- 319 16. Mini G, Mohan M, Sarma P, Thankappan K. Multi-morbidity and blood pressure control:
- Results of a cross-sectional study among school teachers in Kerala, India. Indian Journal of Public
- 321 *Health* 2021; **65**(2): 190-3.
- 322 17. Sum G, Koh GC-H, Mercer SW, et al. Patients with more comorbidities have better detection
- 323 of chronic conditions, but poorer management and control: findings from six middle-income
- 324 countries. *BMC Public Health* 2020; **20**(1): 9.
- 325 18. Paulsen MS, Andersen M, Thomsen JL, et al. Multimorbidity and blood pressure control in
- 326 37 651 hypertensive patients from Danish general practice. J Am Heart Assoc 2012; 2(1): e004531.
- 327 19. Tu K, Sodhi S, Kidd M et al. The University of Toronto Family Medicine Report: Caring for
- 328 our Diverse Populations. Toronto, ON; 2020.
- 329 20. Sarkar C, Dodhia H, Crompton J, et al. Hypertension: a cross-sectional study of the role of
- multimorbidity in blood pressure control. *BMC Family Practice* 2015; **16**(1): 98.
- 331 21. Fortin M, Stewart M, Poitras ME, Almirall J, Maddocks H. A systematic review of
- prevalence studies on multimorbidity: toward a more uniform methodology. Ann Fam Med 2012;
- **10**(2): 142-51.

- 334 22. Kone AP, Mondor L, Maxwell C, Kabir US, Rosella LC, Wodchis WP. Rising burden of
- 335 multimorbidity and related socio-demographic factors: a repeated cross-sectional study of Ontarians.
- 336 *Can J Public Health* 2021; **112**(4): 737-47.
- 337 23. Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Defining and measuring chronic
- conditions: imperatives for research, policy, program, and practice. *Prev Chronic Dis* 2013; **10**: E66.
- 339 24. Statistics Canada. Postal CodeOM Conversion File (PCCF), Reference Guide 2017.
- 340 https://www150.statcan.gc.ca/n1/pub/92-154-g/92-154-g2017001-eng.htm (accessed 01/11/2022.
- 341 25. Leung AA, Nerenberg K, Daskalopoulou SS, et al. Hypertension Canada's 2016 Canadian
- 342 Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis,
- Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol 2016; 32(5): 569-88.
- 344 26. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of
- arterial hypertension. Eur Heart J 2018; **39**(33): 3021-104.
- 346 27. Whelton PK, Carey RM, Aronow WS, et al. 2017
- 347 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,
- 348 Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American
- 349 College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
- 350 *Hypertension* 2018; **71**(6): e13-e115.
- 351 28. Tapela N, Collister J, Clifton L, Turnbull I, Rahimi K, Hunter DJ. Prevalence and
- determinants of hypertension control among almost 100 000 treated adults in the UK. Open Heart
- 353 2021; **8**(1): e001461.

358

- 29. Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence
- and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-
- representative studies with 104 million participants. *The Lancet* 2021; **398**(10304): 957-80.

Table 1: Patient characteristics

360

	Controlled BP (N=43303)	Uncontrolled BP (N=24082)	Overall (N=67385)
Age (years)	,	-	-
Mean (SD)	70.3 (11.6)	69.6 (12.2)	70.1 (11.8)
Median [Min, Max]	70.0 [47.0, 111]	69.0 [47.0, 110]	70.0 [47.0, 111]
Age group (years)			
45-74 years	30562 (70.6%)	17256 (71.7%)	47818 (71.0%)
75-84 years	8927 (20.6%)	4486 (18.6%)	13413 (19.9%)
85+ years	3814 (8.8%)	2340 (9.7%)	6154 (9.1%)
Sex			
Female	22637 (52.3%)	13132 (54.5%)	35769 (53.1%)
Male	20666 (47.7%)	10950 (45.5%)	31616 (46.9%)
Income Quintiles			
1 (low income)	8984 (20.7%)	5090 (21.1%)	14074 (20.9%)
2	7812 (18.0%)	4328 (18.0%)	12140 (18.0%)
3	7264 (16.8%)	3938 (16.4%)	11202 (16.6%)
4	7572 (17.5%)	4177 (17.3%)	11749 (17.4%)
5 (high income)	10693 (24.7%)	5976 (24.8%)	16669 (24.7%)
Missing	978 (2.3%)	573 (2.4%)	1551 (2.3%)
Multimorbidity			
No	7473 (17.3%)	5574 (23.1%)	13047 (19.4%)

	Controlled BP (N=43303)	Uncontrolled BP (N=24082)	Overall (N=67385)
Yes	35830 (82.7%)	18508 (76.9%)	54338 (80.6%)
Body mass index level			
Missing	7831 (18.1%)	5018 (20.8%)	12849 (19.1%)
18.4 or less (Underweight)	267 (0.6%)	145 (0.6%)	412 (0.6%)
18.5 - 24.9 (Normal)	6453 (14.9%)	3220 (13.4%)	9673 (14.4%)
25 - 29.9 (Overweight)	13470 (31.1%)	6999 (29.1%)	20469 (30.4%)
30 - 34.9 (Obese Class I)	9278 (21.4%)	5095 (21.2%)	14373 (21.3%)
35 - 39.9 (Obese Class II)	3782 (8.7%)	2208 (9.2%)	5990 (8.9%)
40 or more (Obese Class III)	2222 (5.1%)	1397 (5.8%)	3619 (5.4%)
Most recent smoking status			
Missing	11062 (25.5%)	6740 (28.0%)	17802 (26.4%)
Current	4219 (9.7%)	2542 (10.6%)	6761 (10.0%)
Non-Smoker	19999 (46.2%)	10868 (45.1%)	30867 (45.8%)
Past	8023 (18.5%)	3932 (16.3%)	11955 (17.7%)
Cancer			
No	37881 (87.5%)	21349 (88.7%)	59230 (87.9%)
Yes	5422 (12.5%)	2733 (11.3%)	8155 (12.1%)
Ischemic Heart disease			
No	37182 (85.9%)	21679 (90.0%)	58861 (87.4%)
Yes	6121 (14.1%)	2403 (10.0%)	8524 (12.6%)

Heart failure

No	Controlled BP (N=43303) 40754 (94.1%)	Uncontrolled BP (N=24082) 23082 (95.8%)	Overall (N=67385) 63836 (94.7%)
Yes	2549 (5.9%)	1000 (4.2%)	3549 (5.3%)
Atrial fibrillation			
No	38362 (88.6%)	21878 (90.8%)	60240 (89.4%)
Yes	4941 (11.4%)	2204 (9.2%)	7145 (10.6%)
Diabetes Mellitus			
No	28126 (65.0%)	17210 (71.5%)	45336 (67.3%)
Yes	15177 (35.0%)	6872 (28.5%)	22049 (32.7%)
Chronic Kidney disease			
No	35292 (81.5%)	20021 (83.1%)	55313 (82.1%)
Yes	8011 (18.5%)	4061 (16.9%)	12072 (17.9%)
Chronic Obstructive Pulmonary Disease			
No	39365 (90.9%)	22197 (92.2%)	61562 (91.4%)
Yes	3938 (9.1%)	1885 (7.8%)	5823 (8.6%)
Osteoarthritis			
No	26654 (61.6%)	15500 (64.4%)	42154 (62.6%)
Yes	16649 (38.4%)	8582 (35.6%)	25231 (37.4%)
Dementia			
No	39774 (91.9%)	22422 (93.1%)	62196 (92.3%)
Yes	3529 (8.1%)	1660 (6.9%)	5189 (7.7%)
Depression and/or Anxiety			

	Controlled BP (N=43303)	Uncontrolled BP (N=24082)	Overall (N=67385)
No	28943 (66.8%)	16728 (69.5%)	45671 (67.8%)
Yes	14360 (33.2%)	7354 (30.5%)	21714 (32.2%)
Schizophrenia			
No	42726 (98.7%)	23853 (99.0%)	66579 (98.8%)
Yes	577 (1.3%)	229 (1.0%)	806 (1.2%)

Comparisons between patients with controlled and uncontrolled BP were assessed using Pearson chisquare tests for categorical covariates and two-sample t-tests for continuous covariates. All p-values <0.001




Figure 1: Flowchart for the generation of this cross-sectional cohort




Figure 2: Percentage of patients with uncontrolled blood pressure




Figure 3: Unadjusted and adjusted odds ratios for uncontrolled blood pressure with respect to patient characteristics. *Odds ratio >1 means a greater likelihood of uncontrolled blood pressure.

Models were adjusted for age, sex, income quintiles, smoking status, body mass index, and number of visits.




Figure 4: Unadjusted and adjusted odds ratios for uncontrolled blood pressure with respect to individual long-term conditions. *Odds ratio >1 means a greater likelihood of uncontrolled blood pressure. Models were adjusted for age, sex, income quintiles, smoking status, body mass index, and number of visits.

Supplementary data

428

429

430

432

433

Figure S1: Directed acyclic graph for the effect of multi-morbidity on blood pressure control




Table S1: Unadjusted and adjusted odds ratios for uncontrolled blood pressure with respect to

434 patient characteristics

Type	Contrast	Odds ratios	Upper	Lower	P-value
Unadjusted odds	Total number of primary care visits: 9+ visits v.s. 0-2 visits	0.73827	0.79546	0.68520	< 0.001
ratios					
Unadjusted odds	Total number of primary care visits: 6-8 visits v.s. 0-2	0.78719	0.83093	0.74576	<0.001
ratios	visits				
Unadjusted odds	Total number of primary care visits: 3-5 visits v.s. 0-2	0.80753	0.83877	0.77746	<0.001
ratios	visits				
Unadjusted odds	Smoking Status: Past v.s. Non Smoker	0.92141	0.96352	0.88113	<0.001
ratios					
Unadjusted odds	Smoking Status: Current v.s. Non Smoker	1.01420	1.07104	0.96038	0.612
ratios					
Unadjusted odds	BMI level: 40 or more (Obese Class III) v.s. 18.5 - 24.9	1.20424	1.31402	1.10364	<0.001

ratios	(Normal)				
		11000	4.00.450		2.224
Unadjusted odds	BMI level: 35 - 39.9 (Obese Class II) v.s. 18.5 - 24.9	1.12685	1.20470	1.05403	<0.001
ratios	(Normal)				
Unadjusted odds	BMI level: 30 - 34.9 (Obese Class I) v.s. 18.5 - 24.9	1.07457	1.13840	1.01432	0.015
ratios	(Normal)				
Unadjusted odds	BMI level: 25 - 29.9 (Overweight) v.s. 18.5 - 24.9	1.03133	1.08717	0.97836	0.251
ratios	(Normal)				
Unadjusted odds	BMI level: 18.4 or less (Underweight) v.s. 18.5 - 24.9	1.11997	1.37281	0.91370	0.275
ratios	(Normal)				
Unadjusted odds	Income Quintiles: 4 v.s. 5	0.98538	1.03246	0.94044	0.536
ratios					
Unadjusted odds	Income Quintiles: 3 v.s. 5	0.97333	1.02475	0.92448	0.303
ratios					
Unadjusted odds	Income Quintiles: 2 v.s. 5	0.97613	1.02786	0.92701	0.359
ratios					
Unadjusted odds	Income Quintiles: 1 v.s. 5	0.97758	1.02763	0.92997	0.373
ratios					
Unadjusted odds	Sex: Male v.s. Female	0.91376	0.94975	0.87915	<0.001
ratios					
Unadjusted odds	Age group: 75-84 years v.s. 85+ years	0.81139	0.86227	0.76352	<0.001
ratios					
Unadjusted odds	Age group: 45-74 years v.s. 85+ years	0.88376	0.94439	0.82703	<0.001
ratios					
Unadjusted odds	Multimorbidity: Yes v.s. No	0.69121	0.71972	0.66384	<0.001
ratios					
Adjusted odds ratios	Total number of primary care visits: 9+ visits v.s. 0-2 visits	0.81565	0.89297	0.74502	<0.001
Adjusted odds ratios	Total number of primary care visits: 6-8 visits v.s. 0-2	0.82926	0.88645	0.77576	<0.001
	visits				
Adjusted odds ratios	Total number of primary care visits: 3-5 visits v.s. 0-2	0.81522	0.85468	0.77759	<0.001
	visits				
Adjusted odds ratios	Smoking Status: Past v.s. Non Smoker	0.93085	0.97948	0.88463	0.006
Adjusted odds ratios	Smoking Status: Current v.s. Non Smoker	1.14532	1.22043	1.07484	<0.001
Adjusted odds ratios	BMI level: 40 or more (Obese Class III) v.s. 18.5 - 24.9	1.33611	1.47065	1.21388	<0.001
,	(Normal)				
Adjusted odds ratios	BMI level: 35 - 39.9 (Obese Class II) v.s. 18.5 - 24.9	1.23587	1.34055	1.13938	<0.001
. rajustou ouds ratios	(Normal)	1.23307	1.34033	1.13/30	
Adimend a 11 and		1 15571	1 22207	1.00240	<0.001
Adjusted odds ratios	BMI level: 30 - 34.9 (Obese Class I) v.s. 18.5 - 24.9	1.15571	1.23387	1.08249	<0.001

	(Normal)				
Adjusted odds ratios	BMI level: 25 - 29.9 (Overweight) v.s. 18.5 - 24.9	1.08476	1.15337	1.02024	0.009
	(Normal)				
Adjusted odds ratios	BMI level: 18.4 or less (Underweight) v.s. 18.5 - 24.9	1.03778	1.32207	0.81462	0.764
	(Normal)				
Adjusted odds ratios	Income Quintiles: 4 v.s. 5	0.96900	1.03199	0.90985	0.327
Adjusted odds ratios	Income Quintiles: 3 v.s. 5	0.96202	1.02630	0.90176	0.241
Adjusted odds ratios	Income Quintiles: 2 v.s. 5	0.98320	1.04831	0.92213	0.604
Adjusted odds ratios	Income Quintiles: 1 v.s. 5	1.00317	1.06821	0.94208	0.921
Adjusted odds ratios	Sex: Male v.s. Female	0.89949	0.93914	0.86152	<0.001
Adjusted odds ratios	Age group: 75-84 years v.s. 85+ years	0.80118	0.87470	0.73384	<0.001
Adjusted odds ratios	Age group: 45-74 years v.s. 85+ years	0.77803	0.84269	0.71832	<0.001
Adjusted odds ratios	Multimorbidity: Yes v.s. No	0.71761	0.75742	0.67990	<0.001

Table S2: Mean number of primary care visits for patients with and without multi-morbidity

438 (annually)

435

436

Mean (standard deviation) number of primary	mult	imorbidity
care visits annually	No	Yes
2017	2.14 (2.17)	3.80 (3.44)
2018	2.30 (2.22)	3.88 (3.36)
2019	2.44 (2.19)	3.91 (3.28)
Frequen	cy (N, column %)	
	2017	
0-2 visits	8599	22134

	65.91	40.73
3-5 visits	3523	19794
	27.00	36.43
6-8 visits	729	7838
	5.59	14.42
9+ visits	196	4572
	1.50	8.41
	2018	
0-2 visits	8219	21141
	63.00	38.91
3-5 visits	3813	20635
	29.23	37.98
6-8 visits	779	8143
	5.97	14.99
9+ visits	236	4419
	1.81	8.13
	2019	
0-2 visits	7934	20688
	60.81	38.07

3-5 visits	4024	21156
	30.84	38.93
6-8 visits	846	8145
	6.48	14.99
9+ visits	243	4349
	1.86	8.00

Table S3: Patient characteristics for sub-optimal blood pressure control (≥130/80 mmHg)

	Controlled BP	Uncontrolled BP	Overall	
	(N=19535)	(N=47850)	(N=67385)	P-value
Age (years)				
Mean (SD)	72.1 (11.5)	69.2 (11.9)	70.1 (11.8)	<0.001
Median [Min, Max]	72.0 [47.0, 111]	69.0 [47.0, 110]	70.0 [47.0, 111]	
Age group (years)				
45-74 years	12809 (65.6%)	35009 (73.2%)	47818 (71.0%)	<0.001
75-84 years	4597 (23.5%)	8816 (18.4%)	13413 (19.9%)	
85+ years	2129 (10.9%)	4025 (8.4%)	6154 (9.1%)	
Sex				
Female	10183 (52.1%)	25586 (53.5%)	35769 (53.1%)	0.00652
Male	9352 (47.9%)	22264 (46.5%)	31616 (46.9%)	
Income Quintiles				
1 (low income)	4259 (21.8%)	9815 (20.5%)	14074 (20.9%)	<0.001
2	3605 (18.5%)	8535 (17.8%)	12140 (18.0%)	

	Controlled BP	Controlled BP Uncontrolled BP		P-value
	(N=19535)	(N=47850)	(N=67385)	r-value
3	3223 (16.5%)	7979 (16.7%)	11202 (16.6%)	
4	3323 (17.0%)	8426 (17.6%)	11749 (17.4%)	
5 (high income)	4626 (23.7%)	12043 (25.2%)	16669 (24.7%)	
Missing	499 (2.6%)	1052 (2.2%)	1551 (2.3%)	
Aultimorbidity				
No	2528 (12.9%)	10519 (22.0%)	13047 (19.4%)	<0.001
Yes	17007 (87.1%)	37331 (78.0%)	54338 (80.6%)	
ody mass index level				
Missing	3347 (17.1%)	9502 (19.9%)	12849 (19.1%)	<0.001
18.4 or less (Underweight)	152 (0.8%)	260 (0.5%)	412 (0.6%)	
18.5 - 24.9 (Normal)	3226 (16.5%)	6447 (13.5%)	9673 (14.4%)	
25 - 29.9 (Overweight)	6190 (31.7%)	14279 (29.8%)	20469 (30.4%)	
30 - 34.9 (Obese Class I)	4043 (20.7%)	10330 (21.6%)	14373 (21.3%)	
35 - 39.9 (Obese Class II)	1630 (8.3%)	4360 (9.1%)	5990 (8.9%)	
40 or more (Obese Class III)	947 (4.8%)	2672 (5.6%)	3619 (5.4%)	
lost recent smoking status				
Missing	4935 (25.3%)	12867 (26.9%)	17802 (26.4%)	<0.001
Current	1909 (9.8%)	4852 (10.1%)	6761 (10.0%)	
Non Smoker	8856 (45.3%)	22011 (46.0%)	30867 (45.8%)	
Past	3835 (19.6%)	8120 (17.0%)	11955 (17.7%)	
ancer				
No	16955 (86.8%)	42275 (88.3%)	59230 (87.9%)	<0.001
Yes	2580 (13.2%)	5575 (11.7%)	8155 (12.1%)	
schemic Heart disease				
No	16032 (82.1%)	42829 (89.5%)	58861 (87.4%)	<0.001

	Controlled BP	Uncontrolled BP	Overall	P-value
	(N=19535)	(N=47850)	(N=67385)	P-value
Yes	3503 (17.9%)	5021 (10.5%)	8524 (12.6%)	•
Heart failure				
No	18006 (92.2%)	45830 (95.8%)	63836 (94.7%)	<0.001
Yes	1529 (7.8%)	2020 (4.2%)	3549 (5.3%)	
Atrial fibrillation				
No	16799 (86.0%)	43441 (90.8%)	60240 (89.4%)	<0.001
Yes	2736 (14.0%)	4409 (9.2%)	7145 (10.6%)	
Diabetes Mellitus				
No	11842 (60.6%)	33494 (70.0%)	45336 (67.3%)	<0.001
Yes	7693 (39.4%)	14356 (30.0%)	22049 (32.7%)	
Chronic Kidney disease				
No	15193 (77.8%)	40120 (83.8%)	55313 (82.1%)	<0.001
Yes	4342 (22.2%)	7730 (16.2%)	12072 (17.9%)	
Chronic Obstructive Pulmonary Disease				
No	17487 (89.5%)	44075 (92.1%)	61562 (91.4%)	<0.001
Yes	2048 (10.5%)	3775 (7.9%)	5823 (8.6%)	
Mental health				
No	11804 (60.4%)	30997 (64.8%)	42801 (63.5%)	<0.001
Yes	7731 (39.6%)	16853 (35.2%)	24584 (36.5%)	

Table S4: Adjusted odds ratios using GEE model for sensitivity analysis using ≥ 130/80 mmHg as

the threshold for sub-optimal blood pressure control.

Contrast	Adjusted odds ratios	Lower	Upper	P-value
Multimorbidity: Yes vs. No	0.56	0.54	0.59	<0.001
Age group: 45-74 years vs. 85+ years	1.29	1.22	1.37	<0.001
Age group: 75-84 years vs. 85+ years	0.98	0.92	1.05	0.582
Sex: Male vs. Female	0.91	0.88	0.94	<0.001
Income Quintiles: 1 vs. 5	0.93	0.88	0.98	0.005
Income Quintiles: 2 vs. 5	0.95	0.90	1.00	0.062
Income Quintiles: 3 vs. 5	0.97	0.92	1.02	0.34
Income Quintiles: 4 vs. 5	0.98	0.93	1.03	0.405
Region: Urban vs. Rural	0.84	0.78	0.90	<0.001

Table S5: Unadjusted and adjusted odds ratios for uncontrolled blood pressure with respect to co-

450 morbidities

Type	Contrast	Odd ratios	Lower	Upper	P-Value
Unadjusted odds ratios	Ischemic Heart Disease: Yes vs. No	0.66969	0.63707	0.70399	<0.001
Unadjusted odds ratios	Heart Failure: Yes vs. No	0.71025	0.65731	0.76745	<0.001
Unadjusted odds ratios	Atrial Fibrillation: Yes vs. No	0.79316	0.75169	0.83692	<0.001
Unadjusted odds ratios	Diabetes Mellitus: Yes vs. No	0.73233	0.70360	0.76223	< 0.001
Unadjusted odds ratios	Chronic Obstructive Pulmonary Disease: Yes vs. No	0.82250	0.77670	0.87100	<0.001
Unadjusted odds ratios	Chronic Kidney Disease: Yes vs. No	0.90107	0.86078	0.94326	<0.001
Unadjusted odds ratios	Osteoarthritis: Yes vs. No	0.88485	0.85331	0.91755	<0.001
Unadjusted odds ratios	Cancer: Yes vs. No	0.88660	0.84844	0.92646	<0.001
Unadjusted odds ratios	Dementia: Yes vs. No	0.85688	0.80274	0.91466	<0.001
Unadjusted odds ratios	Depression and/or Anxiety: Yes vs. No	0.87679	0.84454	0.91028	<0.001
Unadjusted odds ratios	Schizophrenia: Yes vs. No	0.78581	0.67154	0.91952	<0.001

Adjusted odds ratios	Ischemic Heart Disease: Yes vs. No	0.73727	0.68770	0.79041	<0.001
Adjusted odds ratios	Heart Failure: Yes vs. No	0.81404	0.72606	0.91268	< 0.001
Adjusted odds ratios	Atrial Fibrillation: Yes vs. No	0.92968	0.86071	1.00417	0.064
Adjusted odds ratios	Diabetes Mellitus: Yes vs. No	0.73368	0.70013	0.76885	<0.001
Adjusted odds ratios	Chronic Obstructive Pulmonary Disease: Yes vs. No	0.98163	0.90611	1.06344	0.65
Adjusted odds ratios	Chronic Kidney Disease: Yes vs. No	0.94286	0.88606	1.00330	0.063
Adjusted odds ratios	Osteoarthritis: Yes vs. No	0.88625	0.84715	0.92716	<0.001
Adjusted odds ratios	Cancer: Yes vs. No	0.95232	0.89199	1.01672	0.143
Adjusted odds ratios	Dementia: Yes vs. No	0.86759	0.79505	0.94675	0.001
Adjusted odds ratios	Depression and/or Anxiety: Yes vs. No	0.90557	0.86453	0.94856	<0.001
Adjusted odds ratios	Schizophrenia: Yes vs. No	0.79424	0.65170	0.96795	0.022

Appendix

- The appendix section contains the following sections:
- i) Drug names for different classes of hypertension medications;
- 460 ii) Definition for the hypertension phenotype;
- 461 iii) Definition for primary care visit in UTOPIAN database;

The following search criteria were used to identify hypertension medication:

Drug class	Search criteria
name	
ACE	%medication(in=ACE,
inhibitors	
	search='benazepril Lotensin captopril Capoten Captotec Captril cilazapril Inhib
	ace Inhibase enalapril Vasotec fosinopril Monopril Iisinopril Zestril Prinivil per
	indopril Coversyl quinapril

	hcl Accupril Accupro ramipril Altace trandolapril Mavik');
ARB inhibitors	%medication(in=ARB,
	search='candesartan Atacand eprosartan Teveten irbesartan Avapro losartan Cozaar olmesartan Olmetec telmisartan Micardis valsartan Diovan');
Calcium channels	%medication(in=Ca_channel,
	search='amlodipine Norvasc diltiazem Cardizem Tiazac felodipine Renedil Plen dil nicardipine Cardene nifedipine Adalat nimodipine Minotop verapamil Isop tin Veralan Veramil');
Beta- blockers	%medication(in=beta_blockers,
	search='acebutolol Monitan Sectral Rhotral atenolol Tenormin bisoprolol Mon ocor labetalol Trandate metoprolol Lopressor Toprol Betaloc nadolol Corgard oxprenolol Trasicor pindolol Visken propranolol Inderal Detensol');
Diuretics	%medication(in=diuretics, search='amiloride Midamor spironolactone Aldactone triamterene Neo Diurex chlortalidone Thiazide Hygroton hydrochlorothiazide Oretic Microzide

	Diuchlor H Esidrix Hydro Aquil Hydrodiuril Neo Codema Urozide Apo-
	Hydro indapamide Lozide');
Other classes	**********
of	
hypertension	Others includes
medication	- Renin Inhibitor
	- Alpha-2 Adrenergic Receptor Agonist
	- combination medications

	%medication(in=others,
	search=
	'aliskiren Basilez clonidine Catapres Catapresan Kapvay Dixarit methyldopa D
	opazide Methazide Doparil
	benazepril & hydrochlorothiazide Lotensin
	cilazapril & hydrochlorothiazide Inhibace Plus
	enalapril & hydrochlorothiazide Vaseretic
	ramipril & hydrochlorothiazide Altace HCT
	lisinopril & hydrochlorothiazide Zestoretic Prinzide
	perindopril & indapamide Coversyl Plus
	perindopril & amlodipine Viacoram

quinapril & hydrochlorothiazide | Accuretic | amlodipine & telmisartan|Twynsta| azilsartan & chlortalidone | Edarbyclor | eprosartan & hydrochlorothiazide | Teveten Plus | candesartan & hydrochlorothiazide | Atacand Plus | hydrochlorothiazide & irbesartan | Avalide | hydrochlorothiazide & losartan | Hyzaar | hydrochlorothiazide & olmesartan | Benicar HCT | Olmetec Plus | valsartan & hydrochlorothiazide | Diovan HCT | losartan & hydrochlorothiazide | Hyzaar | telmisartan & hydrochlorothiazide | Micardis HCT | Micardis Plus | valsartan & sacubitril|Entresto| atenolol & chlortalidone | Tenoretic | atenolol & hydrochlorothiazide| felodipine & metoprolol|Logimat|Mibloc|Mobloc|Logimax|Forte|Mobloc Forte| nadolol & bendroflumethiazide | Corzide | pindolol & hydrochlorothiazide | Viskazide | propranolol & hydrochlorothiazide | Inderide | timolol & hydrochlorothiazide | Timolide | felodipine & ramipril | Inotens | Unimest And Unitens |

verapamil & trandolapril | Tarka | chlortalidone & reserpine | Regroton | methyldopa & hydrochlorothiazide | Aldoclor | Aldoril | clonidine & chlortalidone | Clorpres | Combipres | reserpine & hydrochlorothiazide | Hydroserpine | Hydropres | Serpasil Esidrix | reserpine & hydrochlorothiazide | hydralazine hcl Ser-Ap-ES | Serpazide | Uni Serp | Hydrap-Es | Diuretic-Ap-Es | Marpres | Serathide | Unipres | Serpex | metoprolol & hydrochlorothiazide | Dutoprol | Lopressor HCT | metoprolol & chlortalidone | Lopressidone | Logroton | amiloride & hydrochlorothiazide | Amiloride HCTZ | Amihydro | Riva-Amilzide | Amilzide | Amilzide | Atenidone | Moduretic | spironolactone & hydrochlorothiazide | Aldactazide | Spirozide | Spirozine | triamterene & hydrochlorothiazide | Dyazide | Maxzide | Diazide | Pro Triazide | Triamzide | Riva-Zide | Triazide | Hydro-Triam');

Hypertension phenotype

480

481

482

483

484

485

We defined the hypertension phenotype using the following criteria:

 Free text documentation of hypertension in the past or present health condition section of the cumulative patient included at least one of the following terms:

488	Include	Do not include
489	Hypertension	Hypertensive response
490	Hypertensive	Borderline
491	Htn	Occular/ocular
492		Maternal
493		Gestation
494		White coat
495		Pulmonary
496		Pregnancy induced/PIH

- Anti-hypertensive medication (listed above) was prescribed and an elevated blood pressure
 reading was recorded at any point in the EMR
 - a. elevated blood pressure reading is defined as systolic blood pressure >= 140 mmHg or diastolic blood pressure >= 90 mmHg
- 501 OR

499

500

502

503

486

- 3. Anti-hypertensive medication (listed above) was prescribed and a billing record with the diagnosis code for hypertension (401) was found at any point in the EMR
- 504 OR

- A billing record with the diagnosis code for hypertension (401) was found and an elevated blood pressure reading was recorded at any point in the EMR
 - a. elevated blood pressure reading is defined as systolic blood pressure >= 140 mmHg or diastolic blood pressure >= 90 mmHg

Definition for primary care visit in UTOPIAN database

505

506

507

508

509

510

511

512

513

OHIP service codes billed during the study period (Jan 2017 to Dec 2019) were used to select family physician visits that occurred via telephone, video, or in-person. Billing records for eligible patients containing any of the following service codes were counted as family physician visits:

Code	Description	Code	Description
A001	minor assessment	K017	periodic health visit-child aft. 2nd birthday
A002	enhanced 18-month well baby visit	K022	hiv prim care individ care 1/2 hr or major part
A003	major assessment	K028	sexually transmitted disease (std) counseling
A004	general re-assessment	K030	diabetic management fee
A007	intermediate assessment	K032	gp-specific neurocognitive assessment
A008	mini assessment	к033	counselling - 1 pt/yr/unit
A071	complex medical specific re- assessment	К039	smoking cessation follow-up visit
A131	complex medical specific re- assessment	K130	periodic health visit - adolescent

A134	medical specific re-assessment	K131	periodic health visit - adult aged 18 to 64 inclusive
A624	medical specific re-assessment	K132	periodic health visit - adult 65 years of age and older
A888	partial assessment	K680	substance abuse - extended assessment
A903	pre-op assessment	P003	obsprenatal care-gen.assess-major prenatal visit
A920	medical management of early pregnancy, initial visit	P004	obsprenatal care-minor prenatal assesssubseq.prenat.vis.
K005	primary mental health	P005	antenatal health screen
K007	ind. psychotherapy per half hour - gp	P008	obspost-natal care in office
K013	counselling-one or more people-per 1/2hr	К037	fibromyalgia/chronic fatigue syndrome care
K080	Minor assessment of patient by telephone or video	K081	Intermediate assessment including psychotherapy by telephone or video
K082	Psychotherapy, psychiatric or mental health counselling by telephone or video	K087	Minor assessment of an uninsured by telephone or video
K088	Intermediate assessment of an uninsured patient including psychotherapy by telephone or video	K089	Psychotherapy, psychiatric or mental health counselling of an uninsured patient by telephone or video